Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Development, optimization, and assessment of losartan nano-bilosomes to mitigate diabetes-induced microvascular complications in Sprague Dawley rats
Journal of Drug Delivery Science and Technology
February 2024
Qushawy M.
Targeted drug delivery strategy: a bridge to the therapy of diabetic kidney disease
Drug Delivery
2023
Chen X.
Open Access
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Frontiers in Physiology
15 February 2022
Dhore-patil A.
Open Access
Captopril and Spironolactone can Attenuate Diabetic Nephropathy in Wistar Rats by Targeting ABCA1 and microRNA-33
Current Pharmaceutical Design
2022
Ghaffari T.
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis
American Journal of Health System Pharmacy
15 December 2021
Villa-Zapata L.
All Open Access, Green
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
Frontiers in Pharmacology
28 October 2021
Kawanami D.
Open Access
Efficacy and safety of dual vs single renin-angiotensin-aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials
Medicine United States
3 September 2021
Zhao M.
Open Access
Organoprotective effects of spironolactone on top of ramipril therapy in a mouse model for alport syndrome
Journal of Clinical Medicine
1 July 2021
Rubel D.
Open Access
Mineralocorticoid receptor antagonists in diabetic kidney disease
Pharmaceuticals
June 2021
Vodošek Hojs N.
Open Access
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
Cochrane Database of Systematic Reviews
27 October 2020
Chung E.Y.M.
All Open Access, Green
Efficacy and Safety of Dual Blockade of the Renin–Angiotensin–Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis
American Journal of Cardiovascular Drugs
1 June 2019
Feng Y.
Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
International Urology and Nephrology
1 April 2019
Dong D.
Open Access
The ascent of mineralocorticoid receptor antagonists in diabetic nephropathy
Current Clinical Pharmacology
2019
Goenka L.
Open Access
Effect of Kangxianling Decoction on Renal Fibrosis and ACE-Ang II-AT1R Axis in 5/6 Nephrectomized Rats
Chinese Journal of Experimental Traditional Medical Formulae
January 2019
Ji J.
Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
Journal of Diabetes Investigation
July 2017
Sun L.J.
Open Access
Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: A randomized controlled trial in a sub-Saharan African population
BMC Research Notes
23 March 2016
Djoumessi R.N.
Open Access
Reporting quality assessment of randomized controlled trials published in nephrology urology monthly journal
Nephro Urology Monthly
1 July 2015
Mehrazmay A.
Open Access
Drugs targeting RAAS in the treatment of hypertension and other cardiovascular diseases
Pathophysiology and Pharmacotherapy of Cardiovascular Disease
1 January 2015
Balakumar P.
Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy
Journal of Diabetes Research
2015
Wang S.
Open Access